3rd Obesity & Weight Loss Drug Development Summit West 2026

 

Optimizing Tolerability, Quality of Weight Loss & Personalized Therapies to Drive Competitive Drug Development

As obesity drug development enters a defining new chapter, the race is no longer about developing the next GLP-1, but delivering the next breakthrough in tolerability, muscle preservation, patient adherence, precision medicine, and long-term outcomes.

With hundreds of obesity assets in development and billions invested in the space, 2026 is a pivotal moment for companies to differentiate their pipelines and benchmark their strategies.

The 3rd Obesity & Weight Loss Drug Development Summit West is where pharma and biotech leaders come together to answer the questions shaping the next decade of obesity therapeutics. This summit is dedicated to the practical challenges and strategic decisions driving drug development success.

Bringing together 80+ senior executives and decision-makers, this intimate forum offers opportunities to exchange insights, build meaningful partnerships, and understand what today’s innovation really means for tomorrow’s therapies.

 

More Info

---

---